 Rafael
Holdings and Rafael Pharmaceuticals have announced a planned merger to create an integrated pharmaceutical company developing novel cancer therapies. The merged company would adopt the Rafael Pharmaceuticals, Inc. name and would include Rafael Holdings' interests in LipoMedix
Pharmaceuticals Ltd. and the Barer Institute, a wholly-owned subsidiary developing a pipeline of compounds focused on the regulation of cancer
metabolism. |
|
|
